05 May 2021
27 April 2021
NEW YORK and LONDON – 27 April 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO...
Read more13 April 2021
Accustem Sciences Limited ("Accustem"), intends to file a listing application with the Nasdaq Stock Market
Read moreOur mission is to bring breakthrough therapies to patients with the aim of treating Crohn's Disease, COVID-19, Pro-MS and HCC and optimizing health outcomes.
Learn moreWith two Phase II and two pre-clinical candidates our development portfolio is supported by extensive IP and a strong pipeline of in-licensed clinical and pre-clinical assets.
Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and a neurodegenerative indication.
Learn more about ForalumabMilciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.
Learn more about MilciclibWith several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipeline of in-licenced clinical and pre-clinical assets.
We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for certain patients infected with COVID-19.
Learn more about Anti IL-6RTiziana is currently conducting clinical development programs for Foralumab and Milciclib
Tiziana reported postive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 2 for both orally administered Foralumab for the treatment of Crohn's disease and nasally administered Foralumab for the treatment of Pro-MS is anticipated to be complete in Q2 2021.
See more Foralumab clinical trialsWe reported positive Phase 2a clinical data exhibiting positive clinical activity with Milciclib Monotherapy in advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma. We intend to initiate Phase 2b with Milciclib in Combination with a TKI in Q2 2021
See more Milciclib clinical trials
